VASCULAR CLINICAL TRIALS
CLI & AMI

Blood and Bone Marrow

CLIRST III Clinical Trial

SurgWerks™

Cesca’s SurgWerks Platform is a vision for the future of regenerative medicine to enable a complete therapy delivered at point of care, intra-operatively in the surgical suite. Each step of the procedure has been optimized for rapid collection, processing, quality assessment and delivery of autologous bone marrow cells, minimizing variability and optimizing therapeutic outcome.

CellWerks™

The CellWerks Platform provides an integrated protocol, disposable and equipment for rapid intra-laboratory use for delivering concentrated hematopoietic stem cells for use according to local regulatory approval. The platform is based on our patented AutoXpress® technology, a functionally closed system that delivers concentrated stem cell component of blood in under one hour with minimal manipulation. This platform addresses bioprocessing, cell expansion protocols, and biobanking.

Bone Marrow Transplant

Cesca’s Bone Marrow Program: At the core of successful clinical outcomes is the maintenance of cell viability and potency prior to delivery. Cesca’s technology for bone marrow processing is designed to optimize the delivery of a therapeutic dose of bone marrow cells for oncology applications.
****************************************************************************************************
Our TotipotentRX GMP laboratory facilities in India provide services and consulting for clinical sample preparation as well as contract research services.

News Updates

Texas Stem Cell Enters into an Agreement with Cesca Therapeutics for U...

February 9, 2016

RANCHO CORDOVA, Calif and Houston, Texas – February 09, 2016 – Cesca Therapeutics Inc. (NASDAQ: ...

Read More >>

Cesca Announces $15 Million Strategic Investment from Boyalife Group.

February 3, 2016

RANCHO CORDOVA, Calif., February 2, 2016 -- Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous ce...

Read More >>

CESCA THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE IN SAN FRANCISCO ON ...

January 8, 2016

RANCHO CORDOVA, Calif., January 7, 2015 - Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous ...

Read More >>

Cesca Therapeutics Sponsors First Symposium on Haploidentical Stem Cel...

January 5, 2016

RANCHO CORDOVA, Calif –January 5, 2016 – Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous ce...

Read More >>
Our Products for Cellular Bioprocessing

Video Library